FDA Approves Herceptin Biosimilar Ontruzant for HER2-Positive BC

Options
Moderators
Moderators Member Posts: 25,912
edited February 2019 in HER2+ (Positive) Breast Cancer

FDA Approves Herceptin Biosimilar Ontruzant for HER2-Positive Breast Cancer
February 6, 2019
On Jan. 20, 2019, the U.S. Food and Drug Administration approved Ontruzant, a biosimilar for Herceptin. Read more...

· Share on FacebookShare on Twitter

Categories